Three MEK inhibitors, CI-1040, Sorafenib and LY294002, were tested and provided evidence that, even in vivo, the inhibition of this pathway is able to suppress both human angiosarcoma and canine HSA proliferation [90]. Here, ALB is linked to angiosarcoma.